Please assess the completion status of the following clinical trial:

Trial Title: OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females, age 11-40~* Histologic evidence of EoE~* History of clinical symptoms of EoE including dysphagia~* Willing to continue with dietary, environmental or medical therapy~* Ability to read and understand english~* Written Consent~Exclusion Criteria:~* Any Medical condition that may compromise the safety of the subjects or interfere with the signs and symptoms of EoE~* Use of immunomodulatory therapy~* Current use of swallowed corticosteroids~* Esophageal strictures,varices or upper GI bleed~* Other current diseases of the GI tract~* Current viral infection or immunodeficiency condition~* Pregnancy~* Hypersensitivity to budesonide~* History of non compliance

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Oral Budesonide Suspension (Type: EXPERIMENTAL): Taken once or twice daily for up to 40 weeks
- Matching Placebo (Type: PLACEBO_COMPARATOR): Taken once or twice daily for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).